Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
- CAS Registry Number
- 1032568-63-0
- Molecular formula
- C23H28N8O4
- Molecular weight
- 480.5 g/mol
- Drug class
- Phosphatidylinositol-3-kinase (PI3K) inhibitortargeted antineoplastic kinase inhibitor (withdrawn US indication)
- Mechanism of action
- Inhibits class I PI3K isoforms, with activity against PI3K-alpha and PI3K-delta, reducing downstream AKT signalling involved in tumour-cell proliferation and survival.
- Indications / reported uses
- Historical US indication: treatment of adults with relapsed follicular lymphoma after at least two systemic therapies. The US approval for ALIQOPA was withdrawn in 2023 following voluntary withdrawal; do not present this as a current US-authorised treatment.
Identification source: PubChem record (CID 135565596). The linked PubChem record is provided for identity reference. Confirm the exact salt, hydrate, isomer, mixture, or product form against authoritative source documentation when defining the assessment scope.